Theme: Prospects and Development of Prophylactic & Therapeutic Vaccines

Vaccines 2015

Renowned Speakers

Vaccines 2015

The scientific sessions of “ Vaccines-2015” housing all the current research in vaccines & vaccination research, Virology Vaccines, Ebola Virus Vaccines and Therapeutics, Veterinary, Polio Vaccine, Cancer Vaccines. Cancer imaging, Diabetes Vaccines, HIV/AIDS Vaccine  Histological Specimens, Bio-defense Vaccine, Therapeutic Vaccine and more other related topics discussed in this prestigious scientific meeting.

With the generous response and support received from the participants of previous annual vaccines conferences. OMICS International proudly announces “9th  Global Summit and Expo on Vaccines & Vaccination (Vaccines-2015).” which will be held during Nov 30-Dec 02, 2015 in San Francisco, USA. The Theme of the conference is “Prospects and Development of Prophylactic & Therapeutic Vaccines”. For more

                                 
Join us in San Francisco for the leading annual Vaccines event and

Find the latest developments in Vaccines and Vaccination
Lectures by the world's prominent vaccinenologists and poster presentations at every career stage
Network Vaccines and Vaccination with colleagues from more than 50 countries
Awareness on novel tools and techniques to benefit your research
For more details on the relevant conferences, please click here

Contact
Venkatesh
Program Manager
Global Vaccines Conferences (Since 2011)
Email: [email protected]
Phone: +1-650-268-9744

Book your slots to attend as a Speaker/Delegate
 http://vaccines.global-summit.com/america/registration.php
 

Malaria vaccine

Malaria is a parasitic infection transmitted to humans through the bites of infected mosquitoes. The resulting disease in humans can be devastating. Malaria is characterized by fever and flu-like symptoms, including chills, headache, body aches and fatigue; these symptoms may occur at intervals. Malaria may be associated with anemia and jaundice, and may cause kidney failure, coma and death. Although a malaria vaccine is technically feasible, making a vaccine to protect people against a parasite has never been done.

Vaccines for TB

Tuberculosis (TB) is a serious infection which affects the lungs, but it can affect other parts of the body such as the bones, joints and kidneys. It can also cause meningitis. Although TB can be a very serious disease, it is possible to make a full recovery from most forms of TB with treatment. Bacille Calmette-Guérin (BCG) is a vaccine for tuberculosis (TB) disease

HIV/ aids vaccines

Vaccines have been our best weapon against the world’s deadliest infectious diseases, including smallpox, polio, measles, and yellow fever. An effective preventive AIDS vaccine would teach the body how to prevent HIV infection. Vaccines are the most powerful public health tools available and an AIDS vaccine would play a powerful role in ensuring the end to the AIDS epidemic. An HIV vaccine does not yet exist, but efforts to develop a vaccine against HIV, the virus that causes AIDS, have been underway for many years

Vaccines research in USA

More than 50,000 people die in the U.S each year from diseases that could have been prevented with a simple vaccine. The Global market research analysis for Vaccines approved by BCC. Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017, for DNA vaccines was valued at $305.3 million in 2014, and further to $2.7 billion by 2019, influenza market will grow from nearly $6 billion in 2018.  The protein therapeutics market is expected to decline to $136.7 billion in 2013 and then increase too nearly $179.1 billion in 2018, for Multiple Sclerosis (MS) disease-modifying products is expected to grow to nearly $14.2 billion in 2018. A compound annual growth rate (CAGR) of 5.6% over the five-year period from 2013 to 2018.

For more details of scientific sessions and submission of abstract, please follow: http://vaccines.global-summit.com/america/call-for-abstracts.php

Vaccines technology 

Prominent market players of vaccines technology  market are Bavarian Nordic (Denmark), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson and Johnson (U.S.), MedImmune, LLC (U.S.), Merck and Company (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Sanofi Pasteur (France).

Preventable disease vaccines

The use of preventable vaccines is to avoid the occurrence of an infectious disease, which is preventable by the use of vaccines. TechNavio's analysts forecast the Global Preventable Vaccines market to grow at a CAGR of 10.16 percent over the period 2014-2019. Major factors driving growth of vaccine technology market include rising prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. Topics related to vaccines development and vaccines safety will be covered by international speaker’s. This provide a forum for researchers, professionals and policy makers to present, share and exchange the latest cutting edge discoveries in vaccines and vaccinations. We hope to facilitate new collaborations between experts in the field and inspire new and innovative ideas in vaccine development.

Emerging diseases

Emerging infectious diseases represent a grave threat to animal and human populations in terms of their impact on global health, agriculture and the economy. Vaccines developed for emerging infections in animals can protect animal health and prevent transmission of zoonotic diseases to humans. The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. Major factors driving growth of vaccine technology market include rising prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations.

Zoster vaccine conferences

Anyone who has had chicken pox is at risk for developing shingles. It is estimated that 1 million or more cases occur each year in the United States. Shingles can occur in people of all ages and the risk increases as people get older. When shingles develop, a rash or blisters appear on the skin, generally on one side of the body. This is a sign that the virus, that has been dormant in the nerve cells, has reactivated and travelled from the nerves and followed a path out to the skin. Because the nerves along the path become inflamed, shingles can also be painful. Pain that lasts for months after the rash has healed is called post herpetic neuralgia or PHN. For some people, this pain can be severe and chronic. Researchers found that overall (in persons age 60 years and older) the vaccine reduced the occurrence of herpes zoster (shingles) by about 50%. The vaccine effect was highest at 64% in people between the ages 60-69, but its effectiveness declined with increasing age; to 41% for the 70-79 age group, and 18% for those 80 years of age and older.

Veterinary vaccine:

The major goals of veterinary vaccines are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent animal-to-human transmission from both domestic animals and wildlife. These diverse aims have led to different approaches to the development of veterinary vaccines from crude but effective whole-pathogen preparations to molecularly defined subunit vaccines, genetically engineered organisms or chimeras, vectored antigen formulations, and naked DNA injections. successful veterinary vaccines have been produced against viral, bacterial, protozoa, and multicellular pathogens, which in many ways have led the field in the application and adaptation of novel technologies, These veterinary vaccines have had, and continue to have, a major impact not only on animal health and production but also on human health through increasing safe food supplies and preventing animal-to-human transmission of infectious diseases. The continued interaction between animals and human researchers and health professionals will be of major importance for adapting new technologies, providing animal models of disease, and confronting new and emerging infectious diseases.

Ebola vaccine:

Ebola haemorrhagic fever is a highly contagious disease that causes death in up to 90 percent of those infected with the virus. Furthermore, there is no treatment that will cure the infection once it begins; therefore, preventing the spread of the virus is crucial to containing outbreaks. This is one reason why research scientists are actively studying a possible Ebola vaccine. At this point, there is not a licensed vaccine for humans; however, an Ebola vaccine has shown to be effective in monkeys based on recent research findings, a single shot of a fast-acting, experimental vaccine successfully protected monkeys from the deadly Ebola virus after only one month. If this vaccine proves similarly effective in humans, it may one day allow scientists to quickly contain outbreaks with ring vaccination, which is the same strategy that was successfully used against smallpox, This research has enormous public health implications, not only because it might be used to limit the spread of Ebola virus, which continues to emerge in central Africa, but also because this vaccine strategy may be applied to other highly lethal viruses that cause acute disease outbreaks and require a rapid response such as the Marburg and Lassa fever viruses, and the severe acute respiratory syndrome (SARS) coronavirus.

Influenza Vaccine:

Influenza is a serious disease that can lead to hospitalization and sometimes even death. Every flu season is different, and influenza infection can affect people differently. Even healthy people can get very sick from the flu and spread it to others. Flu vaccines cause antibodies to develop in the body about two weeks after vaccination. These antibodies provide protection against infection with the viruses that are in the vaccine. The seasonal flu vaccine protects against the influenza viruses that research indicates will be most common during the upcoming season. Traditional flu vaccines (called trivalent vaccines) are made to protect against three flu viruses; an influenza A (H1N1) virus, an influenza A (H3N2) virus, and an influenza B virus. In addition, there are flu vaccines made to protect against four flu viruses (called “quadrivalent” vaccines). These vaccines protect against the same viruses as the trivalent vaccine and an additional B virus. Flu viruses are constantly changing (called “antigenic drift”) – they can change from one season to the next or they can even change within the course of one flu season. Experts must pick which viruses to include in the vaccine many months in advance in order for vaccine to be produced and delivered on time. 

Vaccines for unconventional Disease:

A vaccine-preventable disease is an infectious disease for which an efficacious preventive vaccine subsists. If a person acquires a vaccine-preventable disease and dies from it, the death is considered a vaccine-preventable death. The most mundane and solemn vaccine-preventable diseases tracked by the World Health Organization (WHO) are: diphtheria, Haemophilic influenza, serotype infection, hepatitis, measles, meningitis, mumps, pertussis, poliomyelitis, rubella, tetanus, tuberculosis, and yellow fever. The WHO reports licensed vaccines being available to obviate, or contribute to the aversion and control of, 25 vaccine-preventable infections. Vaccine-preventable deaths are conventionally caused by a failure to obtain the vaccine in a timely manner. This may be due to financial constraints or to lack of access to the vaccine. A vaccine that is generally recommended may be medically incongruous for a minuscule number of people due to astringent allergies or a damaged immune system.

Developing Next Generation Conjugate Medicine:

Conjugate vaccines are glycoprotein molecules (consisting of a protein and polysaccharide component linked together). These sugars are surface exposed bacterial antigens to which the body will develop an immune replication. The protein carrier is responsible for eliciting a perennial immune replication against the polysaccharide in adolescent children, leading to auspice against infection by the pathogen. The chemical conjugation process is non-concrete so that there is heterogeneity in the final product and batch-to-batch variability occurs. Pharmaceutical companies have made paramount strides in optimizing this process and consequential vaccines are available against pathogens such as Streptococcus pneumonia and MEN A and C. However, the chemistry-predicated process has not been able to tackle other paramount pathogens. Albeit the recombinant DNA approach has many advantages over the chemistry approach, evidence is required to show that safe and immunogenic vaccines can be developed and that the manufacturing process is scalable if a vaccine candidate reaches the market. Albeit there is a paramount amount of work still ahead afore a vaccine candidate is licensed for sale, vigorous evidence is accumulating that recombinant DNA-predicated conjugate vaccine development and manufacturing is a valid approach and that pathogens without available vaccines today are feasible targets.

 Developing Technology:

The ability to move genetic determinants between species using in vitro gene-manipulation techniques has opened up new approaches to vaccine development. This has rapidly grown into an exciting area of research in both academic and industrial laboratories. There are numerous scientific challenges which require multidisciplinary teams to solve problems in creating new immunogens. This has challenged our existing knowledge about protein structure and conformation, microbial pathogenicity and the immune system. Recombinant-DNA techniques are invaluable as tools of analysis and antigen production. The surface of micro-organisms can also be minutely explored with the use of synthetic peptides and monoclonal antibodies. Nevertheless, these new technologies do not allow us to circumvent the need for detailed understanding of pathogens and the disease process. What is apparent from the work carried out so far is that there are few easy answers to vaccine development and it is not realistic to expect rapid solutions to these problems.

Vaccines R&D:

Many organisations working on research, development and production in the field of vaccines. Eg- Crucell focuses on research & development, production and marketing of vaccines and antibodies against infectious diseases. With its current portfolio of vaccines, Crucell is working on hepatitis A/B, paediatric and respiratory infectious diseases and travellers’ diseases. One of its products is Quinvaxem, the first fully liquid vaccine against 5 children’s diseases (diphtheria, tetanus, whooping cough, hepatitis B and HIV). Unisf has bought and distributed over 500 million dosages of this product. Crucell was acquired by Johnson & Johnson pharmaceuticals group in 2011. As a result, Crucell will now operate as the global centre for vaccines within J&J. Falco Biotherapeutics is building a product pipeline with drug candidates for the treatment of inflammatory disorders and infectious diseases by leveraging on the unique properties of ElCams TM - a new generation of novel therapeutic, diagnostic and prophylactic protein-based health care products. The company is also working on its Lactobacillus delivery technology. Mymetics focuses on the development of new generation mucosal and virosome-based vaccines.

New trend in carbohydrate based vaccines:

Glycomics is the study that deals with the structures and functions of carbohydrates. The revelation of novel and incrementing number of numerous biological roles of carbohydrates, glycomics has explored the field of carbohydrate vaccines. Tumour-associated carbohydrate antigens (TACAs) are paramount molecular markers on the cancer cell surface, utilizable for the development of therapeutic cancer vaccines or cancer immunotherapies. However, due to their poor immunogenicity and/or immunotolerance, most TACAs fail to induce T cell-mediated immunity that is critical for cancer therapy. This review summarizes the recent effort to surmount this quandary via constructing TACA conjugates with ameliorated immunogenicity, such as by covalently coupling TACAs to opportune carrier molecules to compose clustered or multi-epitopic conjugate vaccines, coupling TACAs to a T cell peptide epitope and/or an immunostimulant epitope to compose plenarily synthetic multi-component glycoconjugate vaccines, and developing vaccines predicated on chemically modified TACAs, which is cumulated with metabolic engineering of cancer cells.

Vaccines for infectious diseases

The World Health Report From 2000:  

Global infectious diseases -

According to the size of their impact estimated  

1. > 70 millions
Acute respiratory infections (96.7), Diarrhoeal diseases (72.1), HIV/AIDS (89.8)  

2. 20-69 millions
Malaria (45.0), Tuberculosis (33.3), Measles (29.8)  

3. 10-19 millions
Sexually-transmitted infections (19.7), Pertussis (10.9), Tetanus (12.0)  

4. < 10 millions
Lymphatic filariasis and onchocerciasis (6.0), Meningitis (9.8), GI nematode infestations (2.7), Hepatitis (2.8), Leishmaniasis (2), Schistosomiasis (1.9), Trachoma (1.2) and other diseases.

Vaccines for non-Infectious diseases

Non-infectious diseases: These are the Vaccines for diseases which id not caused by the infection

  Alzheimer's disease amyloid protein vaccine
  Breast cancer vaccine
  Ovarian cancer vaccine
  Prostate cancer vaccine
Talimogene Laherparepvec (T-VEC), - Herpes virus engineered to produce immune-boosting molecule

Vaccine Safety: 

Vaccines are some of the safest medical products available, but like any other medical product, there may be risks. Vaccines must be safe for use by as many people as possible, vaccines are developed in accordance with the highest standards of safety. World Health Organization agree that vaccines are even safer than vitamins. Each vaccine's safety is continually monitored, even after it's been introduced. Vaccines are the best defense we have against serious, preventable, and sometimes deadly contagious diseases. Through  vaccine safety monitoring, we also make sure new vaccines are safe for people who are at high risk of complications if they get a disease, such as the elderly, those with chronic medical conditions, and pregnant women. Vaccine safety system ensures that vaccines are as safe as possible. The Food and Drug Administration (FDA) ensures the safety, effectiveness, and availability of U.S.-approved vaccines.

 

Child/pediatric vaccines and vaccination:

Vaccines not only help keep your child healthy, they help all children by stamping out serious childhood diseases. Immunizations have had an enormous impact on improving the health of children. It is important that we continue to protect our children with vaccines because outbreaks of vaccine-preventable diseases can and do occasionally occur in all over the world .Vaccination is one of the best ways parents can protect infants, children, and teens from 16 potentially harmful diseases. Vaccine-preventable diseases can be very serious, may require hospitalization, or even be deadly – especially in infants and young children.

Over 80% of the world's children are now being immunized against the polio virus, and the annual number of cases has been cut from 400,000 in 1980 to 90,000 in the mid-1990s. If the year 2000 goal of eradicating polio is achieved, the United States will be able to save the $270 million a year that is currently spent on polio vaccination. The savings for Western European countries will amount to about $200 million a year.

 

Human Vaccines-Infectious Diseases:

Increase immunization rates and reduce preventable infectious diseases. The increase in life expectancy during the 20th century is largely due to improvements in child survival; this increase is associated with reductions in infectious disease mortality, due largely to immunization. However, infectious diseases remain a major cause of illness, disability, and death. Immunization recommendations in the United States currently target 17 vaccine-preventable diseases across the lifespan.

Healthy People 2020 goals for immunization and infectious diseases are rooted in evidence-based clinical and community activities and services for the prevention and treatment of infectious diseases. Objectives new to Healthy People 2020 focus on technological advancements and ensuring that States, local public health departments, and nongovernmental organizations are strong partners in the Nation’s attempt to control the spread of infectious diseases. Objectives for 2020 reflect a more mobile society and the fact that diseases do not stop at geopolitical borders. Awareness of disease and completing prevention and treatment courses remain essential components for reducing infectious disease transmission.

For more details of scientific sessions and submission of abstract, please follow: http://vaccines.global-summit.com/america/call-for-abstracts.php

San Francisco, More than 50,000 people die in the U.S each year from diseases that could have been prevented with a simple vaccine. Influenza is by far the biggest killer, but there are also regular outbreaks of measles, meningitis, and pertussis. Ebola virus and Pertussis (or whooping cough) is currently epidemic in California. Unvaccinated people can spread disease to other adults and the children too young to be immunized. These are the some of the Global market research analysis for Vaccines approved by BCC. Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017, for DNA vaccines was valued at $305.3 million in 2014, and further to $2.7 billion by 2019, influenza market will grow from nearly $6 billion in 2018.  The protein therapeutics market is expected to decline to $136.7 billion in 2013 and then increase to nearly $179.1 billion in 2018, for Multiple Sclerosis (MS) disease-modifying products is expected to grow to nearly $14.2 billion in 2018. The global protein therapeutics market is expected to decline to $136.7 billion in 2013 and then increase to nearly $179.1 billion in 2018, a compound annual growth rate (CAGR) of 5.6% over the five-year period from 2013 to 2018.

I am pleased to announce the 9th Global Summit and Expo on Vaccines & Vaccination (vaccines-2015) to be held in San Francisco, USA from Nov 30-Dec 02, 2015, with the OMICS International as conference organizer. This follows the success of the Vaccines-2013 meeting in Las Vegas and the Vaccines-2014 meeting recently held in Valencia, Spain.

The theme of Vaccines-2015 will be “Prospects and Development of Prophylactic & Therapeutic Vaccines”. This annual vaccine summit will bring together vaccine researchers, postdoctoral fellows, students, clinicians, epidemiologists, public health professionals and industry representatives from around the world, providing them with the opportunity to report and discuss important scientific challenges and achievements in the vaccine field. Most importantly it will provide great opportunities for creation of new collaborations and linkages between academics, clinicians and industry. Such partnerships will be critical to translation of recent laboratory breakthroughs into the vaccines of tomorrow. Examples of the diverse topics that will be covered in this comprehensive conference include; vaccine antigen discovery, design, manufacture and formulation, animal models, human clinical trials, correlates of vaccine protection, novel delivery technologies, vaccine adjuvant, mucosal immunology, innate immune pathways, T- and B-cell immunology, veterinary vaccines, DNA and RNA vaccines, live vectors, vaccine side effects, epidemiology and immunotherapy, amongst many others. Vaccine areas to be covered will include infectious disease, cancer, autoimmunity, Alzheimer’s disease and allergy. The meeting will focus on both basic immune mechanism studies and clinical vaccine advances. Through attendance at Vaccines-2015, you will be able to share your research results with your colleagues and have opportunities to establish new academic and industry collaborations. We will also invite those presenting at Vaccines-2015 the opportunity to publish a manuscript from their talk in the Journal of Vaccines and Vaccination. Please consider joining us in San Francisco for an exciting vaccine meeting.

 

Do not hesitate to get in touch with me if you have any suggestions or questions regarding the organization of this meeting.

 

Professor Nikolai Petrovsky

President

Global Vaccines Conferences, OMICS International

Director of Endocrinology Medicine

Flinders University

Editor-in-Chief, Journal of Vaccines & Vaccination

Australia

Workshop on

The Provocative Effects of Tumor Genomic Heterogeneity on Immunotherapy

Michael G. Hanna

Founder and Chairman Emeritus
Vaccinogen Inc., USA 
Discoverer - Developer, OncoVAX®
Director, Frederick Cancer Research Center (1975-1983)
USA

 

Exclusive session on

Anti-Cancer Vaccines & Hot Breakthroughts

Marek Malecki MD PhD

President
Phoenix Biomolecular Engineering Foundation
Principal Investigator at the National Institutes of Health
USA

                  

Nikolai Petrovsky

President
Global Vaccines Conferences, OMICS International
Director of Endocrinology Medicine
Flinders University
Editor-in-Chief, Journal of Vaccines & Vaccination
Australia

 

workshop on
Investigator Prospective on Vaccine Studies 
Protocol Development and Execution

William B. Smith, MD, FACC

President of New Orleans Center
Professor of Medicine
University of Tennessee Medical Center
USA

 

Book your slots to attend as a Speaker/Delegate

please visit: http://vaccines.global-summit.com/america/registration.php

 

Our previous attendee’s analysis reveals:

• 90% are involved in or make final purchase decisions
• 60% of our previous conferences visited the Exhibit Floor 3 or more times
• 50% came to keep abreast of new products and technology
• 40% came to find a new supplier, technology or product

Categories Available!!

 

Elite sponsor 
Gold sponsor 
Silver sponsor 
Exhibition sponsor 
Lunch / cocktail sponsor 
Coffee break sponsor 
Conference delegate bag sponsor 
Academic partner 
Corporate partner 
Keynote sponsor 
Outside back cover (color)
Inside front cover (color)
Inside back cover (color) 
Conference Banner Sponsor
 
 
"Vaccines-2015 Organizing Committee" congratulates our previous conference best poster award winners and Young Researcher Award winners. 
 
4th International Conference on Vaccines & Vaccination 
September 24-26, 2014 Valencia, Spain
 
Rong Xu, Cardiff University, UK
Title: IL-34 suppresses Candida albicans induced TNF-α production by M1 macrophages through down-regulation of Dectin-1 and TLR2 expression
 
Daisy Vanrompay, Ghent University, Belgium
 Title: Protection of chickens against Chlamydia psittaci challenge by  mucosal immunization with the major outer membrane protein
 
Silvia Vendetti, Istituto Superiore di Sanita, Italy
  Title: Retinoic acid promotes long lasting mucosal and systemic immune responses after mucosal priming and systemic boosting in mice
 

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date November 30-December 02, 2015
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2 Day 3
Poster Opportunity Closed Click Here to View

Testimonials